🇺🇸 GP2013 in United States

159 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 159

Most-reported reactions

1. Drug Ineffective — 27 reports (16.98%)
2. Febrile Neutropenia — 27 reports (16.98%)
3. Rheumatoid Arthritis — 20 reports (12.58%)
4. Interstitial Lung Disease — 19 reports (11.95%)
5. Product Use In Unapproved Indication — 15 reports (9.43%)
6. Infusion Related Reaction — 12 reports (7.55%)
7. Arthralgia — 11 reports (6.92%)
8. C-Reactive Protein Increased — 10 reports (6.29%)
9. Off Label Use — 9 reports (5.66%)
10. Pain — 9 reports (5.66%)

Source database →

Frequently asked questions

Is GP2013 approved in United States?

GP2013 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for GP2013 in United States?

Sandoz is the originator. The local marketing authorisation holder may differ — check the official source linked above.